KYOWA HAKKO BIO CO., LTD. (President and CEO: Chikakuni Kotani), published a research article titled ‘Effects of Citrulline^*1 Combined with Tadalafil^*2 on Monocrotaline-Induced Pulmonary Hypertension in Rats Compared with Arginine’ on Journal of Novel Physiotherapies.

Summary
Purpose: Tadalafil, phosphodiesterase5 (PDE5) inhibitor, was reported to have a therapeutic effect on pulmonary hypertension (PH) and citrulline is an amino acid to...

KYOWA HAKKO BIO CO., LTD. (President and CEO: Chikakuni Kotani), will have a presentation titled ‘Long term supplementation with L-Ornithine*1 enriched nutrition in Japanese patients with pressure ulcer’ at ESPEN 2015.

Date: September 6th, 2015
Time: 9:00 a.m. - 18:00 p.m.
Program number: SUN-PP175
Place: The international Congress Centre of Lisbon (CCL)

Summary
Elderly...

An affiliate company of KYOWA HAKKO BIO CO., LTD. (President and CEO: Chikakuni Kotani), KYOWA HAKKO BIO ITALIA S.R.L. (Italia, Milan) held its presentation on "Cognizin" during "Vitafoods Europe", the biggest health and functional food exhibition in Europe from 5th to 7th May in 2015. "Cognizin" is Kyowa's brand name of Citicoline, a compound of Kyowa's...

Tokyo, Japan, April 9, 2015 --- Kyowa Hakko Bio Co., Ltd. (Tokyo, Japan, CEO: Chikakuni Kotani, "Kyowa Hakko Bio") announced, THAI KYOWA BIOTECHNOLOGIES CO., LTD. (Rayong Province, Thailand, CEO: Akira Tsukihashi, "THAI KYOWA BIOTECHNOLOGIES"), a subsidiary of Kyowa Hakko Bio, has completed the construction of a new manufacturing plant for amino acids in Thailand.

The market for amino acids has...

Tokyo, Japan, March 16, 2015 --- DAIICHI FINE CHEMICAL CO., LTD. (President: Etsuo Ohshima, "DAIICHI FINE CHEMICAL"), a subsidiary of Kyowa Hakko Bio Co., Ltd. (President and CEO: Shuichi Ishino), will change its company name (trade name) to Kyowa Pharma Chemical Co., Ltd. Effective from October 1, 2015.

The reason for the company name change is to bring imaged business...

Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) delivered a scientific opinion on Citicoline as a novel food ingredient (NFI) and concluded that Citicoline is safe under the proposed uses and use levels (www.efsa.europa.eu/it/efsajournal/doc/3421.pdf ).

Commission Implementing Decision 2014/423/EU of 1 July 2014 authorising Kyowa Hakko Europe the placing...

Following a request from the European Commission, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) delivered a scientific opinion on Citicoline as a novel food ingredient (NFI) and concluded that Citicoline is safe under the proposed uses and use levels  (www.efsa.europa.eu/it/efsajournal/doc/3421.pdf ).

Commission Implementing Decision 2014/423/EU of 1 July 2014 authorising Kyowa Hakko Europe the placing...